Get the Stockscreener App
2.38
0.85%
0.02
Allurion Technologies Inc stock is traded at $2.38, with a volume of 54,860.
It is up +0.85% in the last 24 hours and down -6.30% over the past month.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
See More
Previous Close:
$2.36
Open:
$2.31
24h Volume:
54,860
Relative Volume:
0.04
Market Cap:
$13.90M
Revenue:
$34.75M
Net Income/Loss:
$-24.76M
P/E Ratio:
-0.1983
EPS:
-12
Net Cash Flow:
$-50.91M
1W Performance:
+2.15%
1M Performance:
-6.30%
6M Performance:
-87.10%
1Y Performance:
-95.53%
1-Day Range:
$2.30
$2.39
1-Week Range:
$2.26
$2.5149
52-Week Range:
$2.15
$88.75
Allurion Technologies Inc Stock (ALUR) Company Profile
Name
Allurion Technologies Inc
Sector
Industry
Phone
508-647-4000
Address
11 HURON DR STE 200, NATICK
Compare ALUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALUR
Allurion Technologies Inc
|
2.38 | 13.90M | 34.75M | -24.76M | -50.91M | -12.00 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Allurion Technologies Inc Stock (ALUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-02-24 | Initiated | TD Cowen | Buy |
| Sep-06-24 | Initiated | ROTH MKM | Buy |
| Feb-09-24 | Initiated | Jefferies | Buy |
Allurion Technologies Inc Stock (ALUR) Latest News
Obesity Tech Leader Allurion Sets Q1 2025 Earnings Release Date: Key Updates Expected - Stock Titan
Allurion to Report First Quarter 2025 Financial Results on May 14, 2025 - Bluefield Daily Telegraph
Geode Capital Management LLC Has $213,000 Holdings in Allurion Technologies Inc. (NYSE:ALUR) - Defense World
Allurion Technologies Inc. (NYSE:ALUR) Sees Large Drop in Short Interest - Defense World
Allurion Technologies, Inc. (ALUR) Reports Q4 Loss, Lags Revenue Estimates - MSN
Long Term Trading Analysis for (ALUR) - news.stocktradersdaily.com
4 Medical Product Stocks to Buy From a Challenging Industry - Zacks Investment Research
Allurion announces study on obesity treatment enhancement - MSN
Allurion Technologies gains approval for warrant repricing - Investing.com
12 Consumer Discretionary Stocks Moving In Monday's After-Market Session - Benzinga
(ALUR) Investment Report - news.stocktradersdaily.com
Allurion reschedules special stockholders meeting to April 10 By Investing.com - Investing.com India
Allurion reschedules special stockholders meeting to April 10 - Investing.com
Allurion Gives Shareholders More Time: Key Meeting Rescheduled to April 10 - Stock Titan
Allurion Announces Postponement of Special Meeting of Stockholders - Bluefield Daily Telegraph
Allurion Technologies CEO Gaur Shantanu acquires $26,800 in stock By Investing.com - Investing.com Canada
Allurion Technologies CEO Gaur Shantanu acquires $26,800 in stock - Investing.com India
Allurion Technologies CEO Acquires 8,000 Shares - TradingView
Allurion Technologies’ Earnings Call: Growth Amid Challenges - TipRanks
3 Best Stocks to Buy Now, 3/28/2025, According to Top Analysts - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail
Chardan holds Allurion stock at Neutral with a $2.50 target By Investing.com - Investing.com South Africa
Chardan holds Allurion stock at Neutral with a $2.50 target - Investing.com
Allurion Technologies Inc (ALUR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... By GuruFocus - Investing.com Canada
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - BioSpace
TD Cowen Cuts Allurion Technologies' Price Target to $6 From $16, Buy Rating Maintained - MarketScreener
Earnings call transcript: Allurion Technologies’ Q4 2024 shows revenue drop, strategic shifts By Investing.com - Investing.com South Africa
Earnings call transcript: Allurion Technologies’ Q4 2024 shows revenue drop, strategic shifts - Investing.com
Allurion Technologies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALLURION TECHNOLOGIES Earnings Results: $ALUR Reports Quarterly Earnings - Nasdaq
Earnings Scheduled For March 26, 2025 - Benzinga
What To Expect From Allurion Technologies Inc (ALUR) Q4 2024 Earnings - Yahoo Finance
Allurion Technologies’ (ALUR) “Buy” Rating Reiterated at Roth Mkm - Defense World
Allurion surges on weight loss data from gastric balloon, GLP-1 combo treatment - MSN
Gold Down Over 1%; Micron Technology Shares Fall After Q2 Earnings - Benzinga
Allurion Stock Soars on Promising GLP-1 Combo Results - Wall Street Pit
Promising Potential of Allurion Technologies’ Innovative Approach Supports Buy Rating - TipRanks
Pre-market Movers: IBO, ALUR, GCTK, TELA... - RTTNews
Why Ouster Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
US Stocks Likely To Open Lower, But 'Economic Conditions Don't Signal A Downturn,' Say Analysts As They Expect 'Resilient Earnings' To Lift EquitiesAllurion Technologies (NYSE:ALUR), Accenture (NYSE:ACN) - Benzinga
Allurion reports weight loss and muscle gain with new therapy By Investing.com - Investing.com South Africa
Allurion Technologies Reports Positive Ballon Combination Study Results; Shares Jump - MarketScreener
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence - BioSpace
12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session - Benzinga
Allurion reports weight loss and muscle gain with new therapy - Investing.com India
Revolutionary Weight Loss Results: Allurion Balloon Plus Low-Dose GLP-1 Shows 20% Weight Loss, Preserves Muscle - StockTitan
ALLURION TECHNOLOGIES Earnings Preview: Recent $ALUR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Allurion’s Next-Generation Weight Loss Device Earns New Patents - Medical Product Outsourcing
Allurion Technologies (ALUR) Projected to Post Quarterly Earnings on Thursday - Defense World
Allurion Technologies Inc Stock (ALUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):